[Corrections] Correction to Lancet Oncol 2018; 19: 295 –309
de Boer SM, Powell ME, Mileshkin L, et al. Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial. Lancet Oncol 2018; 19: 295 –309—In this Article, the Open Access licence has been changed from CC-BY-NC-ND to CC BY. This correction has been made to the online version as of March 28,2018. (Source: The Lancet Oncology)
Source: The Lancet Oncology - March 29, 2018 Category: Cancer & Oncology Tags: Corrections Source Type: research
[Corrections] Correction to Lancet Oncol 2017; 18: 1221 –37
Lacas B, Bourhis J, Overgaard J, et al. Role of radiotherapy fractionation in head and neck cancers (MARCH): an updated meta-analysis. Lancet Oncol 2017; 18: 1221 –37—In this Article, a change has been made to the authorship. Adam S Garden has been replaced by Beth Beadle in the authorship list. Beth Beadle has also been added to the investigator list in the supplementary appendix. These corrections have been made to the online version as of March 28, 201 8. (Source: The Lancet Oncology)
Source: The Lancet Oncology - March 29, 2018 Category: Cancer & Oncology Tags: Corrections Source Type: research
[Corrections] Correction to Lancet Oncol 2013; 14: 1067 –76
Sgroi DC, Sestak I, Cuzick J, et al. Prediction of late distant recurrence in patients with oestrogen-receptor-positive breast cancer: a prospective comparison of the breast-cancer index (BCI) assay, 21-gene recurrence score, and IHC4 in the TransATAC study population. Lancet Oncol 2013; 14: 1067 –76—In this Article, the 95% CI curves in figure 3, and the graphs on appendix p 7 and p 10, were found to have been calculated using an incorrect statistical method, and as such the width of the CI lines (not the risk curves) needed to be corrected. (Source: The Lancet Oncology)
Source: The Lancet Oncology - March 29, 2018 Category: Cancer & Oncology Tags: Corrections Source Type: research
[Correspondence] Genetic testing for young women with breast cancer – Authors' reply
It is clear both from our data and that of Kelly Metcalfe and colleagues that long-term survivors of breast cancer with BRCA mutations will probably benefit from bilateral mastectomy.1,2 However, patients will only benefit from avoiding a future primary breast cancer if they survive their first diagnosis. (Source: The Lancet Oncology)
Source: The Lancet Oncology - March 29, 2018 Category: Cancer & Oncology Authors: Diana M Eccles, Ellen R Copson Tags: Correspondence Source Type: research
[Correspondence] Genetic testing for young women with breast cancer
Ellen Copson and colleagues1 reported on the effect of carrying a BRCA1 or BRCA2 mutation on survival in a cohort of young women with breast cancer. They did genetic testing on 2733 patients with breast cancer in the Prospective Outcomes in Sporadic versus Hereditary breast cancer (POSH) cohort in the UK and found 12% carried a BRCA1 or BRCA2 mutation. At 10 years, survival of BRCA carriers and non-carriers was not significantly different. Copson and colleagues did not find a significant protective effect of bilateral mastectomy on breast cancer death after a mean follow-up of 8 ·2 years; however, only 21 (6·2%) women wi...
Source: The Lancet Oncology - March 29, 2018 Category: Cancer & Oncology Authors: Kelly Metcalfe, Mohammad R Akbari, Steven A Narod Tags: Correspondence Source Type: research
[Comment] Guidelines for sub-Saharan Africa: a call for evidence
To address the increasing cancer burden in sub-Saharan Africa, in November, 2017, at the African Organization for Research and Training in Cancer conference in Rwanda, the National Comprehensive Cancer Network (NCCN) and African Cancer Coalition released the first Harmonized Guidelines for sub-Saharan Africa. Although the guidelines provide an excellent opportunity to improve cancer care in this region, they also require region-specific evidence to inform them. (Source: The Lancet Oncology)
Source: The Lancet Oncology - March 29, 2018 Category: Cancer & Oncology Authors: Matthew Painschab, Satish Gopal Tags: Comment Source Type: research
[Comment] The NHS and migrant patients with cancer
In 2017, the National Health Service (NHS) England's National Cancer Programme announced that substantial strides had been made towards the full delivery of the NHS 5-year national cancer strategy, which promises “world-class cancer outcomes” by 2020–21.1 Despite a commitment to improving care, treatment, and support for everyone diagnosed with cancer, access is steadily being restricted for migrant patients with cancer.2,3 (Source: The Lancet Oncology)
Source: The Lancet Oncology - March 29, 2018 Category: Cancer & Oncology Authors: Sophie Williams, Erin Dexter, Jessica L Potter Tags: Comment Source Type: research
[Comment] Adjuvant therapy in colon cancer: less is more
The results of the SCOT trial reported by Timothy Iveson and colleagues1 in The Lancet Oncology establish a new standard of care in the adjuvant treatment of stage III colon cancer. The investigators showed the non-inferiority of treatment with 3 months of adjuvant chemotherapy versus 6 months of the same treatment in terms of 3 year disease-free survival. These results endorse the adoption of a shorter duration of adjuvant chemotherapy. Patients treated with the shorter duration of therapy had significant reductions in adverse events, including a more than halving in the number of grade 2 or worse sensory neuropathy event...
Source: The Lancet Oncology - March 29, 2018 Category: Cancer & Oncology Authors: David H Ilson Tags: Comment Source Type: research
[Editorial] New interventions offer prostate cancer hope
Prostate cancer is one of the most common cancers worldwide, with about 1 ·1 million cases diagnosed annually. Depending on the stage of disease at diagnosis, prostate cancer can be managed with combinations of active surveillance, surgery, radiotherapy, and androgen-deprivation therapy (ADT). However, some men have aggressive disease, in which rising concentrations of p rostate-specific antigen (PSA) herald biochemical relapse and metastatic disease, even after treatment. Currently, no standard treatment is available for these men; however, promising new data from two trials presented at the 2018 ASCO Genitourinary Cance...
Source: The Lancet Oncology - March 29, 2018 Category: Cancer & Oncology Authors: The Lancet Oncology Tags: Editorial Source Type: research
[Articles] Larotrectinib for paediatric solid tumours harbouring NTRK gene fusions: phase 1 results from a multicentre, open-label, phase 1/2 study
The TRK inhibitor larotrectinib was well tolerated in paediatric patients and showed encouraging antitumour activity in all patients with TRK fusion-positive tumours. The recommended phase 2 dose was defined as 100mg/m2 (maximum 100 mg per dose) for infants, children, and adolescents, regardless of age. (Source: The Lancet Oncology)
Source: The Lancet Oncology - March 29, 2018 Category: Cancer & Oncology Authors: Theodore W Laetsch, Steven G DuBois, Leo Mascarenhas, Brian Turpin, Noah Federman, Catherine M Albert, Ramamoorthy Nagasubramanian, Jessica L Davis, Erin Rudzinski, Angela M Feraco, Brian B Tuch, Kevin T Ebata, Mark Reynolds, Steven Smith, Scott Cruicksha Tags: Articles Source Type: research
[News] Austrian MPs vote against smoking ban
On March 22, 2018, the Austrian parliament voted to overturn legislation mandating a total ban on smoking in bars and restaurants. The legislation, which was passed in 2015, had been due to come into force in May 2018. (Source: The Lancet Oncology)
Source: The Lancet Oncology - March 29, 2018 Category: Cancer & Oncology Authors: Talha Khan Burki Tags: News Source Type: research
[News] Venetoclax plus rituximab for chronic lymphocytic leukaemia
Results of a randomised, phase 3 trial have shown that treatment with venetoclax plus rituximab led to improved progression-free survival in patients with relapsed or refractory chronic lymphocytic leukaemia, compared with bendamustine plus rituximab. (Source: The Lancet Oncology)
Source: The Lancet Oncology - March 29, 2018 Category: Cancer & Oncology Authors: Robert Stirrups Tags: News Source Type: research
[News] Nivolumab plus ipilimumab in advanced renal-cell carcinoma
The results of the CheckMate 214 study have shown that treatment with nivolumab plus ipilimumab in patients with advanced renal-cell carcinoma can improve outcomes compared with the current standard of care, sunitinib. (Source: The Lancet Oncology)
Source: The Lancet Oncology - March 29, 2018 Category: Cancer & Oncology Authors: Ashray Gunjur Tags: News Source Type: research
[Comment] An active drug for TRK-positive paediatric solid tumours
Despite the promise of personalised medicine and molecular targeted agents, these approaches have translated into few successful new treatments for childhood cancers. Some drugs that have shown activity in this setting include BRAF inhibitors for V600-mutant gliomas or Langerhans cell histiocytosis, and ALK inhibitors for cancers harbouring ALK-translocations.1,2 In The Lancet Oncology, Theodore W Laetsch and colleagues report the phase 1 results of a first-in-child, phase 1/2 trial of the TRK inhibitor larotrectinib, showing encouraging activity in tumours with NTRK fusions. (Source: The Lancet Oncology)
Source: The Lancet Oncology - March 29, 2018 Category: Cancer & Oncology Authors: Lucas Moreno Tags: Comment Source Type: research
[Articles] Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study
Nivolumab combined with ipilimumab and nivolumab monotherapy are active in melanoma brain metastases. A high proportion of patients achieved an intracranial response with the combination. Thus, nivolumab combined with ipilimumab should be considered as a first-line therapy for patients with asymptomatic untreated brain metastases. (Source: The Lancet Oncology)
Source: The Lancet Oncology - March 27, 2018 Category: Cancer & Oncology Authors: Georgina V Long, Victoria Atkinson, Serigne Lo, Shahneen Sandhu, Alexander D Guminski, Michael P Brown, James S Wilmott, Jarem Edwards, Maria Gonzalez, Richard A Scolyer, Alexander M Menzies, Grant A McArthur Tags: Articles Source Type: research
